Melanoma News and Research

Latest Melanoma News and Research

New UTSW model can predict progression of skin cancer in patients

UT Southwestern Medical Center scientists led by Dr. Sean Morrison, director of the Children's Medical Center Research Institute at UT Southwestern, have developed an innovative model for predicting the progression of skin cancer in patients.

8 Nov 2012

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

7 Nov 2012

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Substantial number of cancer survivors experience poor mental or physical health years after cancer

Survivors of many common cancers enjoy a mental and physical health-related quality of life equal to that of adults who have not had cancer, but survivors of other cancers are in poorer health, according to results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

31 Oct 2012

More than one third of U.S. cancer survivors report poor physical or mental health

Beating cancer is just the first step. More than one third of the 12.6 million cancer survivors in the United States have physical or mental problems that put their overall health in jeopardy, according to researchers at Wake Forest Baptist Medical Center.

31 Oct 2012

Blocking RSK protein activity could improve treatment of skin cancers

Blocking the action of a particular protein in our skin could improve the treatment of skin cancers, according to a study published in Oncogene yesterday by Philippe Roux, a researcher at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC).

31 Oct 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

New findings on how OX40 activation affects T helper cells that target melanoma

Cancers arise in the body all the time. Most are nipped in the bud by the immune response, not least by its T cells, which detect telltale molecular markers-or antigens-on cancer cells and destroy them before they grow into tumors. Cancer cells, for their part, evolve constantly to evade such assassination. Those that succeed become full-blown malignancies. Yet, given the right sort of help, the immune system can destroy even these entrenched tumors.

25 Oct 2012

12-chemokine gene signature can predict presence of lymph node-like structures in MM

Researchers at Moffitt Cancer Center have discovered a unique immune gene signature that can predict the presence of microscopic lymph node-like structures in metastatic melanoma. The presence of these immune structures, the researchers said, appears to be associated with better survival and may indicate the possibility of selecting patients for immunotherapy based solely on the immune-related makeup of their tumors as an approach to personalized medicine.

25 Oct 2012

Malignant melanoma cases increase in Sweden

Malignant melanoma is as much as 35% more common among people who live in Gothenburg and the region's coastal municipalities than those who live inland. Researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, have found that the number of malignant melanoma cases in the Västra Götaland region has quadrupled since 1970.

22 Oct 2012

ACT TIL therapy effective in treating metastatic melanoma

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).

19 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Further evidence against sun bed use

Results from a systematic review and meta-analysis published in the BMJ confirm those from previous studies linking sun bed use with an increased risk for skin cancer.

12 Oct 2012

Nelfinavir slows progress of HER2-positive tumor cells

After screening more than 2,300 drugs for their ability to halt the growth of breast cancer cells, Johns Hopkins researchers have discovered that the anti-HIV drug nelfinavir slows the progress of HER2-positive tumor cells, even if they are resistant to other breast cancer drugs.

12 Oct 2012

Tips to check for skin cancer

Skin cancer is the most common cancer in the United States and finding spots that could be cancerous is as simple as looking at your skin. Now a new video, "Skin Self-Exam: How to Do," from the American Academy of Dermatology demonstrates how to check your skin and what to look for.

10 Oct 2012

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics Corporation announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

10 Oct 2012